In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an 125I-labelled DNA-intercalator

Journal of Drug Targeting

Volumn 19, Issue 9, 2011, Pages 846-855

  Fondell, A ^a   Edwards, K ^b,c   Unga, J ^b   Kullberg, E ^a,b   Park, J W ^d   Gedda, L ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Auger; HER2; Intercalator; Liposome; Tumor targeting

Indexed keywords

ANTHRACYCLINE DERIVATIVE; COMP1 I 125; DAUNORUBICIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IODINE 125; LIPOSOME; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUGER ELECTRON SPECTROSCOPY; CELL CULTURE; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERCALATING AGENTS; IODINE RADIOISOTOPES; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION;

EID: 80054702754     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.589436     Document Type: Article

References (30)

1. Allen BJ. (2008). Clinical trials of targeted alpha therapy for cancer. Rev Recent Clin Trials, 3, 185-191
2. Almgren M, Edwards K, Karlsson G. (2000). Cryo transmission electron microscopy of liposomes and related structures. Colloids and Surfaces, A: Physicochemical and Engineering Aspects, 174, 3-21 (Pubitemid 30628959)
3. Brignole C, Pagnan G, Marimpietri D, Cosimo E, Allen TM, Ponzoni M, Pastorino F. (2003). Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett, 197, 231-235 (Pubitemid 36860016)
4. Chen P, Wang J, Hope K, Jin L, Dick J, Cameron R, Brandwein J, Minden M, Reilly RM. (2006). Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti- CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med, 47, 827-836 (Pubitemid 46768447)
5. Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. (2007). (111) In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med, 48, 1357-1368 (Pubitemid 47242802)
6. Costantini DL, Villani DF, Vallis KA, Reilly RM. (2010). Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS- trastuzumab. J Nucl Med, 51, 477-483
7. Dubochet J, Adrian M, Chang JJ, Homo JC, Lepault J, McDowall AW, Schultz P. (1988). Cryo-electron microscopy of vitrified specimens. Q Rev Biophys, 21, 129-228
8. Eldridge JS, Crowther P. (1964). Absolute determination of 125I. Nucleonics, 22
9. El-Rayes BF, LoRusso PM. (2004). Targeting the epidermal growth factor receptor. Br J Cancer, 91, 418-424 (Pubitemid 39093557)
10. Elgqvist J, Andersson H, Bernhardt P, Bck T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L. (2006). Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab)2. Int J Radiat Oncol Biol Phys, 66, 1228-1237 (Pubitemid 44633526)
11. Fondell A, Edwards K, Ickenstein LM, Sjöberg S, Carlsson J, Gedda L. (2010). Nuclisome: a novel concept for radionuclide therapy using targeting liposomes. Eur J Nucl Med Mol Imaging, 37, 114-123
12. Ghirmai S, Mume E, Tolmachev V, Sjöberg S. (2005). Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives. Carbohydr Res, 340, 15-24 (Pubitemid 40023293)
13. Ginj M, Hinni K, Tschumi S, Schulz S, Maecke HR. (2005). Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med, 46, 2097-2103 (Pubitemid 46657459)
14. Ickenstein LM, Edwards K, Sjöberg S, Carlsson J, Gedda L. (2006). A novel 125I-labeled daunorubicin derivative for radionuclidebased cancer therapy. Nucl Med Biol, 33, 773-783 (Pubitemid 44247737)
15. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. (2006). Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res, 66, 6732-6740 (Pubitemid 44085631)
16. Lundqvist H, Stenerlöw B, Gedda L. (2008) The Auger effect in molecular targeting therapy in Stigbrand T, AGaCJ, ed. Targeted radionuclide tumor therapy, Springer Sciences + Business Media B.V
17. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. (2005). Epidermal growth factor receptortargeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res, 65, 11631-11638 (Pubitemid 41821723)
18. Mayer LD, Bally MB, Cullis PR. (1986). Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta, 857, 123-126 (Pubitemid 16085119)
19. Mendelsohn J, Baselga J. (2000). The EGF receptor family as targets for cancer therapy. Oncogene, 19, 6550-6565 (Pubitemid 32197693)
20. Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. (2004). Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med, 45, 129-137 (Pubitemid 47611619)
21. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. (1990). Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer, 45, 457-461 (Pubitemid 20087192)
22. Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD. (2002). Therapeutic efficacy of anti- ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta, 1591, 109-118 (Pubitemid 35232074)
23. Palanca-Wessels MC, Press OW. (2010). Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer, 116, 1126-1133
24. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. (2002). Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res, 8, 1172-1181 (Pubitemid 35177372)
25. Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, Pagnan G, Piccardi F, Cilli M, Longhi R, Ribatti D, Corti A, Allen TM, Ponzoni M. (2006). Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res, 66, 10073-10082 (Pubitemid 44672061)
26. Press MF, Cordon-Cardo C, Slamon DJ. (1990). Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5, 953-962
27. Ranson M, Sliwkowski MX. (2002). Perspectives on anti-HER monoclonal antibodies. Oncology, 63 Suppl 1, 17-24
28. Stigbrand T, Carlsson J, Adams G. (2008). Targeted Radioanuclide Tumor Therapy. Springer Science & Business Media B.V
29. Wheldon TE, ODonoghue JA. (1990). The radiobiology of targeted radiotherapy. Int J Radiat Biol, 58, 1-21 (Pubitemid 20216890)
30. WHO. (2011). Cancer, fact sheet no 297. available at: http://www.who. int/mediacentre/factsheets/fs297/en/